11hon MSN
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results